Clinical Research Study for Persistent Corneal Epithelial Defects (PCED)
We are currently enrolling participants for a clinical research study evaluating a potential new treatment for Persistent Corneal Epithelial Defects (PCED).
About the Study
- This study is for adults 18 years and older who have a PCED that has lasted at least 7 days before the screening visit.
- The defect size must be between 0.2 mm and 8 mm.
- The study duration is about 56 days.
Why Participate?
By joining, you may have the opportunity to access an investigational treatment not yet widely available, while also helping advance research that could benefit others with PCED in the future.
If you or someone you know has been diagnosed with PCED and are interested in learning more about this study, please contact our team to see if you may qualify.
Interested? Contact Our Research Team
Glaucoma and Ocular Hypertension
-
Stent for the treatment of Primary Open Angle Glaucoma at the time of cataract surgery
Study description on clinicaltrials.gov
Diabetic Retinopathy
-
Oral medication for patients with moderate to severe Diabetic Retinopathy.
Study description on clinicaltrials.gov
Age Related Macular Degeneration
- Epidemiological study of AMD progression (non-interventional)
Pediatric
-
Dextenza for Inflammation and Pain Following Surgery for Pediatric Cataract.
Study description on clinicaltrials.gov
Past Clinical Trials
Eye Center of Northern Colorado is privileged to have worked with many drugs and devices that went on to gain FDA approval and are now used to treat patients every day. Some of these technologies include:
Cataract
- Acrysof Restor IOL
- Acrysof High Toric IOL
- IQ Vivity IOL
- IC-8 IOL
Glaucoma
- Glaukos iStent
- Xen Shunt
- Glaukos iStent Inject
- Glaukos G2-W
- Hydrus Microstent
- Rhopressa
- Simbrinza
- Glaukos iDose TR
- Elios System to Reduce Intraocular Pressure in Combination with Cataract Surgery
Myopia
- Pediatric Myopia Ophthalmic Solution SYD-101
- Progression of Myopia in Pediatric Patients using Atropine Sulphate 0.01% (OT-101)
Presbyopia
- Kamra Inlay
Retina
- Susvimo for Wet Age-related Macular Degeneration
- Diabetic Retinopathy OPL-0401
- Macular Edima Port Delivery System with Lucentis (Pagoda)
- Wet AMD Port Delivery System with Lucentis (Portal)
Dry Eye
- Tyrvaya Nasal Spray
Keratoconus
- Oxygen Enriched Cross-Linking
Inflammation
- Inveltys
- TobraDex
- Nevanac
